Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 194,477 shares, a decline of 81.2% from the September 15th total of 1,032,783 shares. Based on an average trading volume of 1,505 shares, the days-to-cover ratio is currently 129.2 days.
Innovent Biologics Stock Performance
Shares of Innovent Biologics stock remained flat at $12.14 during trading on Monday. 3,256 shares of the stock were exchanged, compared to its average volume of 3,728. Innovent Biologics has a 12 month low of $9.10 and a 12 month high of $15.01. The firm has a 50-day simple moving average of $12.57 and a 200-day simple moving average of $11.39.
Innovent Biologics Company Profile
Innovent Biologics, Inc is a China-based biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines and biosimilars. The company’s research and development activities primarily address oncology, autoimmune diseases, metabolic disorders and other serious medical conditions.
Innovent’s portfolio includes therapies such as TYVYT (sintilimab), an immunotherapy used in certain cancer treatments, and olverembatinib, a targeted therapy for specific forms of chronic myeloid leukemia.
See Also
- Five stocks we like better than Innovent Biologics
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
- Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
